A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: Tiragolumab
DRUG: Atezolizumab
DRUG: Nab-paclitaxel
DRUG: Tiragolumab
DRUG: Atezolizumab
DRUG: Nab-paclitaxel
DRUG: Carboplatin
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Granulocyte colony-stimulating factor (G-CSF)
DRUG: Granulocyte-macrophage colony-stimulating factor (GM-CSF)

Sponsor

Hoffmann-La Roche